- active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
United States · Australia · Belgium - recruitingPHASE1
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This study is testing a new experimental vaccine, CryptiVax-1001, for advanced ovarian cancer. It aims to see if the vaccine is safe and if it can help stop the cancer from coming back after standard treatments. This is the first time it’s being used in patients.
United Kingdom - active not recruitingPHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
This study is for people with ovarian or breast cancer who are already receiving olaparib in a different study and are still benefiting. It allows them to continue getting their treatment if their current study ends, ensuring they keep receiving a medication that is helping them.
United States · Belgium · Bulgaria - active not recruitingPHASE3
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
This study looks at new treatments for ovarian cancer that has come back and is resistant to platinum-based chemotherapy. It combines existing drugs like paclitaxel and bevacizumab with a new drug called pembrolizumab, hoping to stop the cancer from growing for longer.
United States · Australia · Belgium - active not recruitingPHASE3
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This study offers continued access to treatments like Avelumab for people who were in earlier Pfizer studies and are still benefiting. It focuses on several cancers and ensures ongoing care and tracking of their health.
United States · Australia · Belgium - recruitingPHASE2
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
This study is looking into a new treatment called INCB123667 for women with ovarian cancer that has come back or grown despite platinum-based chemotherapy. Researchers want to see if this treatment is safe and effective, especially for cancers with high levels of a protein called Cyclin E1.
United States · Australia · Belgium - recruitingPHASE3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
This study compares a new medicine, INCB123667, with standard chemotherapy for women with ovarian cancer that has grown despite platinum-based treatment and shows specific genetic changes. It aims to see if the new drug works better than current options.
United States · Australia · Belgium - recruitingPHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.
United States · Canada · China - recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
This study looks at a new treatment called sacituzumab tirumotecan, sometimes with another medicine called bevacizumab. We want to see if it's safe and helps women with ovarian, fallopian tube, or primary peritoneal cancer live longer without their cancer getting worse, compared to standard care.
United States · Argentina · Australia - active not recruitingPHASE2
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
This study is looking at a new way to treat advanced ovarian cancer. It combines a drug called olaparib with standard chemotherapy (carboplatin and paclitaxel) to see if it works better and is safe compared to chemotherapy alone.
United States · Australia · Belgium - recruitingPHASE1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
This study is testing a new drug, LY4052031, for people with advanced cancers like bladder, breast, and lung cancer. It aims to see if the drug is safe, what dose works best, and if it helps shrink tumors. It's an early-stage study to gather important information.
United States · Australia · China - recruitingPHASE3
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
This study is for women with advanced ovarian cancer that has responded well to initial treatment. It's testing a new medicine called sac-TMT, sometimes with bevacizumab, to see if it can keep the cancer from growing or coming back for longer than standard care.
United States · Argentina · Australia - active not recruitingPHASE2
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
This study looks at giving olaparib, a new drug, before surgery and chemotherapy for recurrent ovarian, primary peritoneal, or fallopian tube cancer. It aims to see if it can shrink tumours and improve outcomes.
Canada · New Zealand · Spain - active not recruitingPHASE3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
This study is looking at a new treatment for certain types of ovarian, fallopian tube, or peritoneal cancer that have returned after initial treatment. It compares a new drug, mirvetuximab soravtansine, given with bevacizumab, against bevacizumab alone, to see if the new combination can keep the cancer away for longer.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
This study is testing a new drug, TUB-040, for ovarian cancer and a type of lung cancer (non-small cell lung cancer) when standard treatments haven't worked. It checks how safe it is, how it moves in the body, and if it helps shrink tumours. The study aims to find the best dose.
United States · Belgium · Germany - active not recruitingPHASE1, PHASE2
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
This study is testing a new cell therapy called gavo-cel for advanced cancers like mesothelioma and ovarian cancer. It explores how well gavo-cel works, both alone and with other cancer drugs, in people whose tumours produce a specific protein called mesothelin.
United States · Canada - recruiting
13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
This study looks at how cells in ovarian cancer ascites (fluid build-up) use energy. Researchers will give a special, safe form of sugar ([U-13C]glucose) to patients undergoing fluid drainage. This helps them understand cancer and immune cell activity to find better ways to treat this condition.
Canada - recruitingPHASE1
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
This study is testing a new cell therapy called ZI-MA4-1 for certain advanced cancers like ovarian, lung, and head and neck cancer. It's the first time this treatment designed to fight cancer will be given to people, aiming to see if it's safe and how well it works.
United Kingdom - recruitingNA
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
This study looks at a new digital tool called GA-Mainstream. It helps people with certain cancers like breast, ovarian, and colon cancer understand genetic testing better. The goal is to make sure patients feel informed and supported while getting tested for genes that can affect their cancer treatment.
Canada - recruitingNA
Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy
This study looks at blood samples from women with BRCA-mutated ovarian cancer receiving PARP inhibitor treatment. We're searching for specific gene changes in their blood to help identify early signs of the cancer returning, allowing for closer monitoring.
France - recruiting
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
This study is developing new blood tests for early cancer detection and to monitor how well treatment is working. It uses artificial intelligence to look at tiny particles in blood samples from people with various cancers and healthy volunteers.
Argentina · Nigeria · United Kingdom - recruiting
Ovarian Cancer Radiomics Approach in CT Led Evaluation
This study uses a new computer method, called radiomics, to analyse CT scans of ovarian cancer. It aims to see if this detailed scan analysis can help doctors plan more personalised treatment and understand the cancer better, potentially leading to new treatments.
United Kingdom - recruiting
Cancer Loyalty Card Study 2 (CLOCS-2)
This study looks at shopping habits using loyalty card data from Tesco or Boots to see if certain purchases might hint at cancer earlier. It aims to help doctors diagnose pancreatic, bowel, oesophageal, stomach, liver, bladder, womb, vulval, and ovarian cancers sooner.
United Kingdom - recruitingPHASE1, PHASE2
Trial of THEO-260 in Ovarian Cancer Patients
This study is testing a new treatment, THEO-260, for advanced ovarian cancer. It's looking for a safe dose and early signs that it can shrink tumours. Only women aged 18 and over with certain types of ovarian cancer who haven't responded to previous treatments can take part.
Spain · United Kingdom - recruitingPHASE1
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
This study is testing a new cancer medicine, OVM-200, for the first time in people. It involves up to 52 patients with prostate, lung, or ovarian cancer to check if it's safe and how well it works. It's given as an injection under the skin.
United Kingdom - recruitingNA
Feasibility of CALM in Patients With Ovarian Cancer
This study looks at a therapy called CALM for people with ovarian cancer. It explores if CALM is helpful and easy to offer soon after diagnosis or if the cancer comes back, and if it can help with stress.
Canada - recruiting
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
This study looks at how new cancer treatments affect daily life for people with long-term cancer. It aims to understand how to best support them while they are on these treatments, often for many months or years.
Canada - authorisedTherapeutic exploratory (Phase II)
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer.
This study is looking at new ways to treat advanced ovarian cancer that has come back. It tests combinations of new drugs, olaparib, durvalumab, and a vaccine called UV1, to see if they can stop the cancer from growing for longer in patients whose cancer does not have a specific BRCA gene change.
Netherlands · Finland · Norway - active not recruitingPHASE1
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study is testing a new cell therapy for certain cancers that have a specific protein. It aims to see if it's safe and how well people tolerate it. The therapy uses your own modified cells to fight the cancer. Some participants will also receive a small amount of radiation.
United States · Canada - active not recruitingPHASE2
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
This study is for women with ovarian cancer that has come back after treatment with certain drugs (PARP inhibitors). It's looking at new combinations of medicines (tuvusertib with niraparib or lartesertib) to see how well they work and if they are safe.
United States · Australia · Belgium - recruiting
ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients
This study aims to create a tool to predict how well ovarian cancer patients will respond to chemotherapy. It uses samples from surgery and tracks their treatment to help doctors choose the best personal treatment plan.
United Kingdom - recruiting
Clinical Pre-screening Protocol for Ovarian Cancer
This study looks at your ovarian cancer tissue to see if a special test can predict which cancer drugs might work best for you. It helps doctors understand how effective past treatments were and guide future choices.
United States · United Kingdom - recruitingPHASE3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
This study looks at a new drug, Trastuzumab Deruxtecan, combined with an existing treatment, Bevacizumab, for a type of advanced ovarian cancer. It aims to see if this combination works better than Bevacizumab alone after initial chemotherapy.
United States · Australia · Austria - recruitingNA
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
This study looks at a new way to lower ovarian cancer risk in women with certain gene changes. Instead of removing both ovaries and fallopian tubes at once, it explores removing only the fallopian tubes first, and the ovaries later, to delay menopause and its effects. We want to see if this new approach is safe and effective.
United States · Australia · Austria - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - active not recruitingPHASE3
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
This study looks at a new drug, oregovomab, combined with standard chemotherapy for women with advanced ovarian cancer after surgery. Researchers want to see if this combination works better and is safe compared to chemotherapy alone.
United States · Argentina · Belgium - recruitingPHASE3
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
This study compares two ways to treat advanced ovarian cancer: standard chemotherapy plus a medicine called niraparib, versus standard chemotherapy plus two medicines, bevacizumab and niraparib. It aims to see which treatment works best to control the cancer.
Germany - recruiting
Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology
This study looks for clues in your spit to help diagnose common gynaecological problems like endometriosis, ovarian cysts, and cancers. It aims to find new ways to spot these conditions by examining special genetic material (RNA) in saliva.
France - active not recruitingPHASE2
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
This study is for women aged 18-75 with a certain type of ovarian cancer. It tests a new treatment, ADP-A2M4CD8, alone or with nivolumab, to see how well it works and if it's safe.
United States · Canada · France - recruitingPHASE2
Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
This study looks at different ways to give a drug called niraparib to women with advanced ovarian cancer. It aims to find out if changing the dose helps reduce side effects while still being an effective treatment after chemotherapy.
Canada - active not recruitingNA
Trial on Radical Upfront Surgery in Advanced Ovarian Cancer
This study looks at the best time to have surgery for advanced ovarian cancer. It compares having surgery first, then chemotherapy, versus having some chemotherapy first, then surgery, then more chemotherapy, to see which approach works better.
United States · Austria · Denmark - active not recruitingPHASE2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
This study is looking at new treatments for a specific type of ovarian cancer that has come back or won't go away. We want to see if these treatments are safe and effective for patients whose cancer has certain genetic features.
United States · Australia · Canada - recruiting
ROCkeTS GEN V2 Study. Refining Ovarian Cancer Test Accuracy Scores: A test accuracy study to validate new risk scores in postmenopausal women with symptoms of suspected ovarian cancer
This study aims to find better ways to detect ovarian cancer earlier in postmenopausal women with certain symptoms. We want to improve tests so fewer women have unnecessary procedures and worry. It involves blood samples and possibly a tissue sample if you have surgery.
United Kingdom - recruitingPHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.
United States · Australia · United Kingdom - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study
This study looks at a new way to treat ovarian cancer using the body's own immune system. It explores how special cells, called dendritic cells, can be trained to help fight the cancer after initial chemotherapy. It's for women with ovarian cancer who are having chemotherapy before surgery.
Netherlands - authorisedTherapeutic exploratory (Phase II)
Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer
This study looks at a new way to give chemotherapy medicine for advanced ovarian cancer. It's called 'intensive intraperitoneal therapy' and involves putting the medicine directly into the tummy. The aim is to see how safe and effective this treatment is for women with this type of cancer.
France - active not recruitingPHASE1
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This study is testing two anti-cancer drugs, cabozantinib and atezolizumab, alone and together, for various advanced cancers. It aims to find a safe combination dose and see how well it works and any side effects.
United States · Australia · Belgium - authorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)
This study is looking at a new drug (INCB123667) for ovarian cancer that has become resistant to standard chemotherapy. Researchers want to see if this new drug works better than existing chemotherapy options for patients whose cancer has high levels of a protein called Cyclin E1.
Ireland · Poland · France - active not recruitingPHASE1, PHASE2
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
This study is testing a new drug, BT5528, for advanced cancers like ovarian, lung, and breast cancer. We want to find a safe dose, understand side effects, and see how well it works, sometimes given with another drug called nivolumab.
United States · Belgium · South Korea - recruitingPHASE1, PHASE2
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
This study is testing a new medicine called AZD8205, by itself or with other cancer drugs. It's for people with advanced cancers like breast, ovarian, or lung cancer, to see if it's safe and helps shrink tumours.
United States · Australia · Belgium